Milrinone as Compared with Dobutamine in the Treatment of Cardiogenic Shock

RCT (n=192) found no significant difference between milrinone (ML) and dobutamine (DB) in patients with cardiogenic shock with respect to primary composite outcome (event occurred in 47 [49%] on ML and 52 [54%] on DB; RR 0.90; 95% CI, 0.69-1.19; p=0.47) or main secondary outcomes

SPS commentary:

In the trial the primary outcome was composite of in-hospital death from any cause, resuscitated cardiac arrest, receipt of a cardiac transplant or mechanical circulatory support, nonfatal myocardial infarction, transient ischemic attack or stroke diagnosed by a neurologist, or initiation of renal replacement therapy.

New England Journal of Medicine